Seres Therapeutics sheds about 160 jobs to focus on commercial C. diff pill
Seres Therapeutics will end most R&D work to focus resources on its commercial product in a move that will result in letting go about 160 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
